Latest Industry Insights

The study of brain tumors using real-time imaging of the brain in live disease models is critical for elucidating disease mechanisms and developing novel treatment strategies. Such research requires full characterization of healthy and disease phenotypes using a multi-omics analysis, as described in this blog.

Technology Networks recently spoke with Stephen Williams, CMO at biotechnology company SomaLogic, to learn more about research progress in the proteomics space and the technology that has enabled it.

Technology Networks spoke with Erik Allen, Vice President and General Manager, Specimen Management for BD, to learn more about the advantages of capillary collection and the importance of making diagnostic testing more convenient and comfortable for patients.

Speaking to Technology Networks, Ryan Denomme highlights the key challenges faced when using “traditional” surface plasmon resonance (SPR), how SPR is being used to aid drug discoveries, and explains the benefits of designing an SPR instrument that integrates digital microfluidics, artificial intelligence, and nanotechnology.

Technology Networks spoke with Jonathan Widdowson, Director of ProColl and Enterprise Fellow at the Royal Academy of Engineering Enterprise Hub, to learn more about how yeast can be used to manufacture collagens and the applications of this approach.

Over the last five to ten years, multi-modal imaging has become established as a significant component of a preclinical researcher’s analytical toolbox. Here, we highlight perhaps the most used and certainly the most sensitive and quantitative of these imaging modalities, the combination of positron emission tomography (PET) with X-ray computed tomography (CT), or PET/CT.

Technology Networks recently spoke with LifeArc’s CEO Melanie Lee, PhD, CBE. Melanie elaborates on LifeArc's mission, discusses the importance of bridging the gap between "bench" and "bedside", and highlights how genomics can help drive earlier intervention.

Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex, a lead drug candidate that treats non-small cell lung cancer, and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.

Less than 5% of adult cancer patients enroll in clinical trials even though it is estimated that a large percentage (70% of Americans) are very willing to take part in a clinical study. So, why is there such a large discrepancy in the number of actual participants versus those willing to, but not actually participating?

Technology Networks recently interviewed Ronan Levy, Founder and Executive Chairman of Field Trip Psychedelics, Inc. to find out more about the therapeutic potential of psychedelics and hear about the drugs undergoing clinical investigation.